655 related articles for article (PubMed ID: 30853366)
1. Evaluation and management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Respir Investig; 2019 Jul; 57(4):300-311. PubMed ID: 30853366
[TBL] [Abstract][Full Text] [Related]
2. Practical management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):90-8. PubMed ID: 26278687
[TBL] [Abstract][Full Text] [Related]
3. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
4. Interstitial Lung Disease: A Review.
Maher TM
JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
[TBL] [Abstract][Full Text] [Related]
5. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
6. Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.
Nakano A; Ohkubo H; Fukumitsu K; Fukuda S; Kanemitsu Y; Takemura M; Maeno K; Ito Y; Oguri T; Niimi A
Intern Med; 2019 Apr; 58(8):1141-1144. PubMed ID: 30568147
[TBL] [Abstract][Full Text] [Related]
7. Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Kishaba T
Medicina (Kaunas); 2019 Mar; 55(3):. PubMed ID: 30884853
[TBL] [Abstract][Full Text] [Related]
8. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
[TBL] [Abstract][Full Text] [Related]
10. Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.
Miyamoto A; Morokawa N; Takahashi Y; Ogawa K; Takeyasu M; Murase K; Hanada S; Uruga H; Mochizuki S; Takaya H; Kurosaki A; Kishi K
Intern Med; 2016; 55(6):657-61. PubMed ID: 26984086
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
12. Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Higo H; Miyahara N; Taniguchi A; Senoo S; Itano J; Watanabe H; Oda N; Kayatani H; Ichikawa H; Shibayama T; Kajimoto K; Tanimoto Y; Kanehiro A; Maeda Y; Kiura K;
Respir Investig; 2020 May; 58(3):185-189. PubMed ID: 32102769
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
[No Abstract] [Full Text] [Related]
14. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
[TBL] [Abstract][Full Text] [Related]
15. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
[TBL] [Abstract][Full Text] [Related]
16. Radiological and Physiological Predictors of IPF Mortality.
Kishaba T; Maeda A; Yamazato S; Nabeya D; Yamashiro S; Nagano H
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684158
[No Abstract] [Full Text] [Related]
17. Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels.
Koga Y; Hachisu Y; Tsurumaki H; Yatomi M; Kaira K; Ohta S; Ono J; Izuhara K; Dobashi K; Hisada T
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31108995
[No Abstract] [Full Text] [Related]
18. The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis.
Ishii H; Kinoshita Y; Kushima H; Nagata N; Watanabe K
Chron Respir Dis; 2019; 16():1479973119867945. PubMed ID: 31387379
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis.
Kono M; Fujita Y; Takeda K; Miyashita K; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Enomoto N; Nakamura Y; Suda T; Nakamura H
Respir Med; 2019; 154():122-126. PubMed ID: 31238182
[TBL] [Abstract][Full Text] [Related]
20. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
